Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Has Average Target Price of $8.60

Posted by Brian Himes on Nov 3rd, 2026

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) have received a consensus rating of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $8.60.

A number of equities research analysts have recently issued reports on AQST shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 price objective on shares of Aquestive Therapeutics in a research note on Thursday, September 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Friday, October 16th. Finally, Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th.

Read Our Latest Stock Report on Aquestive Therapeutics

Aquestive Therapeutics Stock Down 3.1%

Shares of AQST opened at $3.77 on Tuesday. The stock has a 50 day simple moving average of $4.64 and a two-hundred day simple moving average of $4.20. Aquestive Therapeutics has a 1 year low of $2.93 and a 1 year high of $6.85.

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The business had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million. On average, equities research analysts forecast that Aquestive Therapeutics will post -0.50 EPS for the current fiscal year.

Insider Transactions at Aquestive Therapeutics

In other news, insider Sherry Korczynski sold 8,750 shares of the business’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total value of $45,675.00. Following the completion of the sale, the insider owned 235,689 shares of the company’s stock, valued at approximately $1,230,296.58. The trade was a 3.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 25,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $4.22, for a total value of $105,500.00. Following the completion of the sale, the chief executive officer directly owned 627,317 shares of the company’s stock, valued at approximately $2,647,277.74. This trade represents a 3.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 58,750 shares of company stock worth $271,675 over the last ninety days. Insiders own 6.81% of the company’s stock.

Hedge Funds Weigh In On Aquestive Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in Aquestive Therapeutics in the 3rd quarter worth $30,000. Profund Advisors LLC raised its stake in shares of Aquestive Therapeutics by 497.9% during the third quarter. Profund Advisors LLC now owns 195,758 shares of the company’s stock valued at $906,000 after acquiring an additional 163,019 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Aquestive Therapeutics by 14.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,901 shares of the company’s stock valued at $107,000 after acquiring an additional 2,936 shares during the last quarter. WINTON GROUP Ltd bought a new position in shares of Aquestive Therapeutics during the second quarter valued at about $210,000. Finally, Engineers Gate Manager LP boosted its holdings in shares of Aquestive Therapeutics by 20.5% during the second quarter. Engineers Gate Manager LP now owns 49,879 shares of the company’s stock worth $207,000 after purchasing an additional 8,496 shares during the period. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

(Get Free Report)

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.